Verrica Pharmaceuticals Inc.
VRCA
$5.19
-$0.07-1.33%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 16.70% | -1.36% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 16.70% | -1.36% | |||
| Cost of Revenue | 45.55% | 21.12% | |||
| Gross Profit | -483.21% | -76.60% | |||
| SG&A Expenses | 3.60% | 23.06% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 17.12% | 22.43% | |||
| Operating Income | -17.33% | -39.86% | |||
| Income Before Tax | -35.85% | -19.92% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -35.85% | -19.92% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -35.85% | -19.92% | |||
| EBIT | -17.33% | -39.86% | |||
| EBITDA | -17.43% | -40.49% | |||
| EPS Basic | -35.87% | 20.59% | |||
| Normalized Basic EPS | -18.31% | -1.87% | |||
| EPS Diluted | -36.44% | 20.59% | |||
| Normalized Diluted EPS | -18.31% | -1.87% | |||
| Average Basic Shares Outstanding | 0.00% | 51.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 51.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||